Representatives McCaul and Van Hollen send letters to the FDA and Teva Pharmacueticals to seek more information about the ongoing shortage of daunorubicin, an essential therapy in the treatment of leukemia in children.
Progress in Developing First Pediatric Cancer Treatments in Decades Highlights 4th Annual Childhood Cancer Summit
Progress into research and development of the first new pediatric cancer drugs in nearly 30 years was announced at the 4th Annual Congressional Childhood Cancer Summit on Capitol Hill on September 19, 2013.
Leaders from NCI and FDA address the third annual Childhood Cancer Summit to discuss federal efforts to combat childhood cancers.
This month, we pay tribute to the families, friends, professionals, and communities who lend their strength to children fighting pediatric cancer.